Starpharma Holdings Ltd has released a press release.
DEP cabazitaxel shows complete, sustained tumour regression
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma signs drug delivery license with AstraZeneca
- Successful completion of VivaGel study sexually active women
- Starpharma`s Bacterial Vaginosis Study gets FDA Clearance
- Starpharma and Lilly Sign New Drug Delivery Collaboration
- Starpharma`s partner SSL acquired by Reckitt Benckiser
Later from Starpharma
- VivaGel active against Zika virus
- Starpharmas DEP eliminates cabazitaxel neutropenia
- Appendix 4C - Quarterly Cashflow Reoprt
- Starpharma signs license for a VivaGel condom in China
- New DEP drug delivery program initiated with AstraZeneca
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma